Amelia Daniel
Impact in
- Infectious Diseases top 1%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Genetics top 5%
- Genetic Associations and Epidemiology
Papers in
-
- COVID-19 Clinical Research Studies 8
- Genetics 8
- Genetic Associations and Epidemiology 6
- Inflammatory Bowel Disease 2
Amelia Daniel
18 papers receiving 2.9k citations
Amelia Daniel's Hit Papers
Peers
Comparison fields: 5 of 105
- Infectious Diseases 1.8k
- Genetics 554
- Applied Microbiology and Biotechnology 35
- Neurology 196
- Internal Medicine 29
Countries citing papers authored by Amelia Daniel
This map shows the geographic impact of Amelia Daniel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amelia Daniel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amelia Daniel more than expected).
Fields of papers citing papers by Amelia Daniel
This network shows the impact of papers produced by Amelia Daniel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amelia Daniel. The network helps show where Amelia Daniel may publish in the future.
No co-authors to show.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Mapping the human genetic architecture of COVID-19 Hit paper breakdown → | 2021 | 656 |
| 2 | Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 411 |
| 3 | Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial Hit paper breakdown → | 2021 | 393 |
| 4 | Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2022 | 282 |
| 5 | Whole-genome sequencing reveals host factors underlying critical COVID-19 Hit paper breakdown → | 2022 | 233 |
| 6 | Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis Hit paper breakdown → | 2022 | 231 |
| 7 | 2021 | 213 | |
| 8 | 2018 | 193 | |
| 9 | GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19 Hit paper breakdown → | 2023 | 125 |
| 10 | Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2023 | 84 |
| 11 | 2019 | 60 | |
| 12 | 2023 | 60 | |
| 13 | 2019 | 48 | |
| 14 | 2022 | 32 | |
| 15 | 2024 | 27 | |
| 16 | 2022 | 11 | |
| 17 | 2024 | 8 | |
| 18 | 2025 | 5 | |
| 19 | 2021 | 0 |
About Amelia Daniel
Amelia Daniel is a scholar working on Infectious Diseases, Genetics, Pulmonary and Respiratory Medicine, Neurology and Radiology, Nuclear Medicine and Imaging, having authored 19 papers that have together received 3.1k indexed citations. Recurring topics across this work include COVID-19 Clinical Research Studies (8 papers), Genetic Associations and Epidemiology (6 papers), Inflammatory Bowel Disease (2 papers), Prostate Cancer Diagnosis and Treatment (1 paper), Intracerebral and Subarachnoid Hemorrhage Research (1 paper), Lung Cancer Diagnosis and Treatment (1 paper), Atrial Fibrillation Management and Outcomes (1 paper) and Prostate Cancer Treatment and Research (1 paper). The work is most often cited by research in Infectious Diseases (1.8k citations), Genetics (554 citations), Applied Microbiology and Biotechnology (35 citations), Neurology (196 citations) and Internal Medicine (29 citations). Amelia Daniel has collaborated with scholars based in United Kingdom, Vietnam and Nepal. Their work appears in journals such as The Lancet, Nature, The Lancet Neurology, Journal of Crohn s and Colitis and Human Genetics and Genomics Advances.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.